IPCALAB2019-01-012019-03-31in-bse-fin:OneOperatingExpenses01Member IPCALAB2019-01-012019-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2018-04-01 2019-03-31 2019-05-08 INR Crores Yearly Single segment Pharmaceuticals 2019-01-01 2019-03-31 Audited Standalone 8338100000.00 145800000.00 8483900000.00 2661400000.00 440400000.00 -412100000.00 1768200000.00 62500000.00 416100000.00 2133500000.00 7070000000.00 1413900000.00 0.00 1413900000.00 309000000.00 10200000.00 319200000.00 0.00 1094700000.00 0.00 0.00 0.00 0.00 1094700000.00 -42800000.00 1051900000.00 0.00 0.00 252700000.00 2 8.67 8.67 0.00 0.00 8.67 8.67 Notes: nThe above audited standalone financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors at their meeting held on May 29, 2019. n2 Effective April 1, 2018, the Company has adopted Ind AS 115 on 'Revenue from Contracts with Customers' using the cumulative catch-up transition method. The adootion of this standard did not have anv material imoact on the above financial results. n3 The Board has recommended a dividend off Rs. 3/- per share (150%) for the financial year 2018-19. n4 In the month of April 2019, the Company has aquired 100% share holding of Ramdev Chemical Private Limited, a company engaged in the business of manufacturing and marketing of advanced drug intermediates, fine chemicals, custom synthesis molecules and active pharmaceutical ingredients. n5 Sales for the quarter April 1, 2017 to June 30, 2017 is inclusive of excise duty. Sales for the period July 1, 2017 to March 31, 2019 is net of Goods and Services Tax. For comparision purposes,sales excluding excise duty is given below: n nSr.No. Particulars Quarter Ended Year Ended n 31.03.2019 31.12.2018 31.03.2018 31.03.2019 31.03.2018 n (Audited) (Unaudited) (Audited) (Audited) (Audited) nA. Total Income from operations 833.81 947.59 781.56 3633.15 3219.21 nB. Excise Duty on sales (included in other expenses) - - - - 10.28 nC. Total Income from operations excluding nExcise duty on Sales 833.81 947.59 781.56 3,633.15 3208.93 n n6 The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review. n7 The Company has only one reportable primary business segment viz. 'Pharmaceuticals'. n8 Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period. 2018-04-01 2019-03-31 Audited Standalone 36331500000.00 545900000.00 36877400000.00 10980200000.00 1678700000.00 -1061400000.00 7522400000.00 184900000.00 1718800000.00 10279900000.00 31303500000.00 5573900000.00 0.00 5573900000.00 1148800000.00 -124000000.00 1024800000.00 0.00 4549100000.00 0.00 0.00 0.00 0.00 4549100000.00 -51400000.00 4497700000.00 0.00 0.00 252700000.00 2 31113900000.00 36.01 36.01 0.00 0.00 36.01 36.01 others 2133500000.00 others 10279900000.00 0.00 0.00 0.00